Welcome to the Frankfurt Foundation Quality of Medicines
Every day, medicinal products make a decisive contribution to prevent diseases – especially serious ones – or alleviating ailments, extending the life expectancy of patients and improving their quality of life. In addition to our high expectations of the efficacy and safety of medicines, the pharmaceutical quality of the products is also particularly important with regard to patient care.
The Frankfurt Foundation Quality of Medicines (FFQM) is committed to promoting research activities that are designated to optimally assure the quality of medicinal products in Germany and Europe or, if necessary, further improving them, especially if they are manufactured outside the country. Main concern is the development of advanced processes, the implementation of innovative technologies and their standardization as well as a critical verification of quality assurance concepts.
Download the FFQM flyer here (PDF-File, ~200kB)
Recent news
April 25, 2024 · Funding Projekts
Follow-up publication to the FFQM funded project "Detection of unexpected impurities in finished medicinal products."
The working group of Prof. Oliver Scherf-Clavel, Ludwig Maximilian University of Munich, has published a further study on impurities in Lorsatan tablets. The results were recently published in the Journal of Pharmaceutical and Biomedical Analysis: Backer et al „Targeted and untargeted screening for impurities in losartan tablets marketed in Germany by means of liquid chromatography/high resolution mass spectrometry“, https://doi.org/10.1016/j.jpba.2024.116160.
In the present study, the LC-MS/HRMS approach described by Backer et al. for the analysis of known and unknown losartan potassium impurities (https://doi.org/10.1016/j.jpba.2023.115955) was applied to an even more complex system in a larger screening context. The present study included 35 losartan drug products and fixed dose combination products purchased in German pharmacies in 2018 and 2022. The film-coated tablets were analyzed using four LC-MS/HRMS method variants. Differences in the impurity profiles of medicines from 2018 and 2022 were observed.
This study demonstrates that broad screening approaches such as this are applicable to the analysis of pharmaceuticals and can contribute to an important improvement in the quality assurance of medicinal products.
April 17, 2024 · Prices and Awards
Pearls of Bioequivalence Award 2024 goes to Prof. James Polli
We congratulate Professor James E. Polli, Department of Pharmaceutical Sciences, University of Maryland, School of Pharmacy, who is this year’s winner of the Pearls of Bioequivalence Award. The prize is awarded jointly by the Frankfurt Foundation Quality of Medicines (FFQM) and the European Federation for Pharmaceutical Sciences (EUFEPS). The award goes to the publication of Prof. Polli:
“Lack of an Effect of Polysorbate 80 on Intestinal Drug Permeability“, Pharmaceutical Research (2022) 39:1881–1890 https://doi.org/10.1007/s11095-022-03312-zis
This prize was awarded at the Global Bioequivalence Harmonization Initiative (GBHI) conference on April 16 in Rockville/MD by the Chairman of the foundation’s Board, Professor Henning Blume.
April 11, 2024 · News
“Medicinal products with pH-dependent solubility - A problem for BA/BE assessment?” FFQM enables Open Access to this ICH M13A commentary.
We are pleased that, following the conference report on the EUFEPS Open Forum on the ICH M13A Draft Guideline (https://doi.org/10.1016/j.ejps.2024.106741), a commentary on the draft guideline „Medicinal products with pH-dependent solubility – A problem for BA/BE assessment? has now also been published in the European Journal of Pharmaceutical Sciences. The FFQM has sponsored open access to the article in order to provide free access to all scientists interested in optimizing drug quality.
The publication can be accessed at
https://doi.org/10.1016/j.ejps.2024.106756
Translated with DeepL.com (free version)
March 17, 2024 · Prices and Awards
Hans-Günter-Schäfer Award 2024
„I hope you will take this award as motivation for your future research as a scientist“. With these words, the Chairman of the Frankfurt Foundation congratulates this year’s winner of the Hans Günter Schäfer Science Award, Ms. Yomna Nassar (Freie Universität Berlin). The prize, endowed with 1,000 euros, is sponsored by the Frankfurt Foundation Quality of Medicines (FFQM).
The award was presented on 15 March on the occasion of the PKPD expert meeting in Isny, which is organized by the Association for Applied Human Pharmacology (AGAH). The past president of the AGAH, Dr. Andreas Kovar, and this year’s chairman of the meeting, Dr. Alexander Staab, present the prize to Yomna Nassar after her summary of the main results of the award-winning publication.
March 10, 2024 · News
Open Forum on ICH draft Bioequivalence Guideline: Conference Report published
We are happy to announce that the Conference Report of the EUFEPS Open Forum on the ICH draft M13A guideline (Bioequivalence) has been published and the Frankfurt Foundation Quality of Medicines could support this by funding its open access publication.
The paper can be downloaded via: https://doi.org/10.1016/j.ejps.2024.106741
March 5, 2024 · News
Quality of Medicines Award 2024 announced.
The Frankfurt Foundation Quality of Medicines (FFQM) and the German Pharmaceutical Society (DPhG) jointly award the the Quality of Medicines prize 2024 for outstanding scientific achievements in the field of optimizing and ensuring the quality of drugs. We would like to support fundamental investigations into the quality of drugs on the market as well as innovative concepts to improve them.
Applications can be submitted electronically to the DPhG office (info@dphg.de) or to the Frankfurt Foundation Quality of Medicines (info@frankfurt-foundation.org) until July 15, 2024.
